TrialDiabetes, obesity & metabolism2025

Evaluation of an oral small-molecule glucagon-like peptide-1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose-ranging, phase 2, randomized, placebo-controlled study.

Neeta B Amin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.